Exelixis Stock News

Exelixis, Inc. (EXEL) Management Presents at 39th Annual J.P. Morgan Healthcare Conference (Transcript)

Exelixis (EXEL) provides preliminary results for the fourth quarter and 2020 along with the annual guidance for 2021. It also throws light on anticipated milestones for 2021.

ALAMEDA, Calif.--(BUSINESS WIRE)--Exelixis, Inc. (Nasdaq: EXEL) today announced its preliminary unaudited financial results for the fourth quarter and full year 2020, provided financial guidance for f

One big biotech and two small biotechs that share a common denominator: Great growth prospects.

Bargains are plentiful for value investors in the new year.

ALAMEDA, Calif.--(BUSINESS WIRE)--Exelixis, Inc. (Nasdaq: EXEL) today announced that Michael M. Morrissey, Ph.D., the company's President and Chief Executive Officer, will provide a corporate overview

The company reported negative results from a clinical trial.

Here's your prescription for huge returns in the upcoming year.

These high-growth companies are big-time bargains for opportunistic investors.

Exelixis' (EXEL) cabozantinib meets the co-primary endpoint in the late-stage study for the treatment of differentiated thyroid cancer following anti-VEGFR therapy.

Getting in on the extensive merger and acquisition game of large pharmaceutical companies is the ultimate endgame for Exelixis, a biotech that already boasts an established cancer-focused product line

ALAMEDA, Calif.--(BUSINESS WIRE)--Exelixis, Inc. (NASDAQ: EXEL) today announced that COSMIC-311, the phase 3 pivotal trial evaluating cabozantinib (CABOMETYX®) versus placebo in patients with radioio

Each of them should enjoy strong sales growth in 2021 and beyond.

ALAMEDA, Calif., SOUTH SAN FRANCISCO, Calif. & VANCOUVER, British Columbia--(BUSINESS WIRE)--Exelixis, Inc. (Nasdaq: EXEL), Iconic Therapeutics, Inc. (Iconic) and Zymeworks Inc. (NYSE:ZYME) today anno

Exelixis, Inc. (EXEL) CEO Mike Morrissey Presents at Evercore ISI 3rd Annual HealthCONx (Transcript)